Celyad Oncology S.A.
0QFK.L
London Stock Exchange0.18
EUR
+0.01
- -
Celyad Oncology S.A.
0QFK.L
(London Stock Exchange)
Recent
price
0.18
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Celyad Oncology S.A. is a Belgium-based biotechnology company that focuses on unlocking the potential of its intellectual property portfolio in chimeric antigen receptor (CAR) T-cell therapies for cancer treatment. The company develops proprietary technology platforms and CAR T-cell candidates, including allogeneic (off-the-shelf) and autologous (patient-derived) therapies targeting hematological malignancies such as acute myeloid leukemia, multiple myeloma, and myelodysplastic syndromes, as well as solid tumors including metastatic colorectal cancer; its key historical candidates encompass CYAD-01, an NKG2D-based autologous CAR T therapy, CYAD-101 for colorectal cancer, CYAD-211 incorporating short hairpin RNA (shRNA) for multiple myeloma, and CYAD-02 for acute myeloid leukemia. Operations center on intellectual property management and licensing following the discontinuation of internal research and development activities in August 2025, with a strategic review exploring asset sales, partnerships, mergers, and financing options amid limited cash resources projected to last into mid-Q4 2025; recent developments include a PIPE financing announcement in July 2025, major shareholding notifications involving Fortress in August 2025, and significant workforce reductions tied to R&D cessation. Founded in 2007 and headquartered at Rue Andre Dumont 9 in Mont-Saint-Guibert, Belgium, Celyad Oncology previously maintained a U.S. presence in New York and conducts its primary activities in Europe through Euronext Brussels (CYAD) and Paris listings.